Carl Minniti, MD
Hematology & Oncology · Mickleton, NJNPI 1811993652
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Incyte Corporation at 29.5% of the total. Reporting peaked in 2019 at $10,071 and has fallen 96.0% since, to $402 in 2025.
Across 56 payments — averaging $329.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$5K
- Exelixis Inc.$3K
- Beigene USA, Inc.$2K
- Athenex Pharmaceutical Division, LLC$2K
- AstraZeneca$1K
- Janssen Scientific Affairs, LLC$1K
- plus $3K from 13 others
Across 12 payments — averaging $14,678 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taiho Oncology, Inc.$80K
- Amgen$73K
- Astrazeneca UK Limited$23K
What the payments were for
- Consulting fees$10,96359%
- Speaking & faculty fees$4,25023%
- Travel & lodging$1,4948%
- Food & beverage$1,6389%
- Education$1311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 12 | $5,442 |
| Exelixis Inc. | 9 | $3,396 |
| Beigene USA, Inc. | 2 | $1,942 |
| Athenex Pharmaceutical Division, LLC | 3 | $1,867 |
| AstraZeneca | 5 | $1,461 |
| Janssen Scientific Affairs, LLC | 1 | $1,170 |
| Jazz Pharmaceuticals Inc. | 1 | $1,100 |
| Morphosys, US Inc. | 1 | $615 |
| ASD Specialty Healthcare, LLC | 3 | $522 |
| E.r. Squibb & Sons, L.L.C. | 5 | $476 |
| Avyxa Pharma, LLC | 1 | $167 |
| Seagen Inc. | 2 | $87 |
| Lilly USA, LLC | 3 | $86 |
| AVEO Pharmaceuticals, Inc. | 2 | $52 |
| Amgen | 2 | $40 |
| Johnson & Johnson | 1 | $15 |
| Sanofi | 1 | $13 |
| Merck | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$3,239
- BRUKINSA$1,925
- TAGRISSO$1,388
- RYBREVANT$1,170
- ZEPZELCA$1,100
- Oral Paclitaxel$800
- Encequidar$800
- MONJUVI$615
- OPDIVO$415
- LUTRATE DEPOT$167
- AVGEMSI$167
- KYXATA$167
How this compares
$18,476 in reported general payments places this provider in the 85th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 43 | $603,580 |
| Lenalidomide | 39 | $578,728 |
| CalquenceAcalabrutinib Maleate | 25 | $373,460 |
| RevlimidLenalidomide | 16 | $353,966 |
| CabometyxCabozantinib S-Malate | 13 | $324,679 |
| ProcritEpoetin Alfa | 70 | $249,164 |
| AlecensaAlectinib Hcl | 12 | $216,245 |
| IbrancePalbociclib | 12 | $183,985 |
| NinlaroIxazomib Citrate | 12 | $151,336 |
| Imatinib Mesylate | 38 | $86,720 |
| EliquisApixaban | 61 | $51,890 |
| RetacritEpoetin Alfa-Epbx | 14 | $15,738 |
| XareltoRivaroxaban | 17 | $13,755 |
| Fentanyl | 20 | $5,840 |
| Hydroxyurea | 64 | $3,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $1,942 | $603,58043 claims |
| AstraZenecaCalquence | $1,461 | $373,46025 claims |
| Exelixis Inc.Cabometyx | $3,396 | $324,67913 claims |
| Johnson & JohnsonProcrit, Xarelto | $15 | $262,91987 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Mickleton
- Tami BachMickleton$25K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Arturo Loaiza-BonillaPennington$406K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.